Lucis, a French startup focused on expanding access to preventive health testing, has closed an $8.5 million seed round led by General Catalyst, with participation from Y Combinator, Kima Ventures, Motier Ventures, Circle.Co, and North South Ventures.
Founded by Maxime Berthelot, Baptiste Debever, and Max Guerois, Lucis offers a platform that translates blood test results into a set of indicators tracked every six to 12 months. It provides a structured view of more than 180 biomarkers, covering areas such as cardiometabolic health, hormones, inflammation, liver and kidney function, and selected micronutrients, with the aim of helping users identify potential imbalances and early signals associated with chronic disease.
The company positions Lucis as a preventive tool to support understanding and monitoring of health, and notes that it does not replace medical consultation, diagnosis, or prescribing.
Our mission is to empower individuals to take ownership of their health by giving them a clear view of key indicators before symptoms even appear, and providing practical guidance to improve their well-being, without replacing physicians,
said Maxime Berthelot, CEO and co-founder of Lucis.
Members complete check-ups through certified medical biology laboratories across Europe. Results are reviewed by a multidisciplinary medical team, with AI used to help surface key signals and track changes over time.
Instead of receiving a static report, users access a dashboard and a prioritised action plan organised around five areas: nutrition, supplements, physical activity, sleep and recovery, and mental health. Lucis positions this model as an extension of broader consumer health tracking, adding biological markers and clinical oversight to support a more structured, public health–aligned approach.
The new funding will be used to accelerate rollout in France, the UK, Ireland, and Portugal and into additional markets, expand its network of partner laboratories and clinicians, and further develop its AI-enabled preventive analysis and support platform.
Would you like to write the first comment?
Login to post comments